NASDAQ:ADAG Adagene Q2 2026 Earnings Results & Report $2.43 -0.03 (-1.06%) As of 09:57 AM Eastern This is a fair market value price provided by Massive. Learn more. Adagene was expected to report Q2 2026 earnings on September 2, 2026. Analysts expected earnings of -$0.22 per share on revenue of $17.50 million. Confirmed results have not been posted yet. This page will update with the reported figures, conference call transcript, and earnings documents as they become available. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Announcement DateSeptember 2, 2026 Adagene EPS ResultsActual EPSN/AConsensus EPS -$0.22Beat/MissN/AOne Year Ago EPSN/AAdagene Revenue ResultsActual RevenueN/AExpected Revenue$17.50 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) Adagene Earnings HeadlinesAdagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference1 hour ago | globenewswire.comAdagene Inc. Sponsored ADR (NASDAQ:ADAG) Stock Has Consensus Price Target of $8.67 According to BrokeragesOctober 9, 2026 | americanbankingnews.comTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower prices before November 3. One small oil and gas company sits atop the largest oil and gas deposit ever found on American soil and is integrating AI technology into its wells, with margins rivaling firms valued ten times higher. A previous stock pick from this same screening process rose more than 1,000 percent in under 12 months.October 14 at 1:00 AM | Monument Traders Alliance (Ad)Adagene Inc. Announces Resignation of Chunfang Gu as Executive Director of Finance, Effective September 30, 2026September 26, 2026 | marketscreener.comMAdagene Inc. Announces NMPA Clearance Of Investigational New Drug Application For ADG138, A Novel HER2xCD3 Double-Masked Bispecific T-Cell EngagerSeptember 24, 2026 | marketscreener.comMAdagene Inc. meldet NMPA-Zulassung des Antrags auf klinische Prüfung (IND) für ADG138, einen neuartigen doppelt maskierten bispezifischen HER2xCD3-T-Zell-EngagerSeptember 23, 2026 | de.marketscreener.comDSee More Adagene Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adagene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adagene and other key companies, straight to your email. Email Address About AdageneAdagene (NASDAQ:ADAG) Inc. is a biotechnology company focused on discovering and developing novel antibody-based cancer immunotherapies. The company combines computational methods, antibody engineering and translational research to create medicines designed to address limitations associated with conventional immuno-oncology treatments. Adagene’s technology platform includes NEObody, which is intended to identify antibodies with differentiated binding characteristics, and SAFEbody, a masking technology designed to conditionally activate antibodies in the tumor microenvironment. These platforms support the company’s efforts to develop therapies directed at immune-regulatory targets, including programs involving checkpoint and costimulatory pathways. Founded in 2017, Adagene has operated with a research and development presence in both the United States and China, serving the global biopharmaceutical market. The company was co-founded and led by Peter Luo, who has served as chief executive officer. Its work has included internal drug development as well as collaborations intended to advance antibody therapeutics.View Adagene ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
